Rani Therapeutics Holdings posts net loss of $31.9 million for Q3 2025
I'm PortAI, I can summarize articles.
Rani Therapeutics Holdings Inc. reported a net loss of $31.9 million for the nine months ended September 30, 2025, a 22% decrease from a net loss of $40.9 million in the same period of 2024. The net loss attributable to the company was $19.4 million, down 8.1% from $21.1 million the previous year. Contract revenue was $0.2 million, attributed to an agreement with Chugai, compared to no revenue in 2024. The company is focused on developing its oral delivery technology and pursuing partnerships with biopharmaceutical firms.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments